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Abstract
Background:  In a significant proportion of metastatic breast cancer (MBC) patients whose
tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally
believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal.
Methods: Data was retrieved from a prospectively updated database of metastatic breast cancer.
Relevant data was exported to SPSS™ software for statistical analysis.
Results: In oestrogen receptor (ER) positive MBC patients with assessable disease, CB was
achieved in 159 (71.3%) (1st line) patients. When these patients were put on further endocrine
therapy, the CB rates were 63.2% (on 2nd line), 46.1% (on 3rd line) and 20% (on 4th line) with a
median duration of response (DOR) in those with CB of 22, 12, 11 and 15 months respectively.
The remaining 64(28.7%) patients had de novo resistance on 1st line endocrine therapy. Seventeen
of these patients were treated with further endocrine therapy. The CB rates were 29.4% (on 2nd
line) and 22.2% (on 3rd line) with a median DOR in those with CB of 22.7 months and 14 months
respectively.
Conclusion: The chance of further endocrine response continues to decrease with each line of
therapy, yet CB is still seen with reasonable duration even with a 4th line agent. In addition, further
endocrine response, with long duration, can be seen in a significant proportion of patients who have
developed de novo resistance to 1st line endocrine therapy. The use of further endocrine therapy
should not be excluded under these circumstances.
Background
Recurrences after initial breast cancer treatment often
manifest systemically as distant metastases. There is, thus,
perpetual need to have effective systemic agents including
endocrine agents to deal with them. Since the advent of
tamoxifen in early seventies, several endocrine agents
have been in vogue. These agents used in appropriate sce-
narios have better side-effect profile over cytotoxic agents.
However, limitation to exploitation of this profile of the
endocrine agents occurs due to the development of resist-
ance after some duration of clinical efficacy.
To counter the effect of resistance to 1st line endocrine
therapy, sequential use of endocrine therapy with chemo-
therapy were starting to be practised in early eighties [1].
Later, sequencing of endocrine agents was possible due to
Published: 05 July 2006
World Journal of Surgical Oncology 2006, 4:40 doi:10.1186/1477-7819-4-40
Received: 26 April 2006
Accepted: 05 July 2006
This article is available from: http://www.wjso.com/content/4/1/40
© 2006 Agrawal et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2006, 4:40 http://www.wjso.com/content/4/1/40
Page 2 of 7
(page number not for citation purposes)
the apparent lack of cross-resistance between individual
endocrine agents. Therefore, changing to a different type
of endocrine agent when resistance develops to one can
circumvent this problem to some extent and delay the
need for cytotoxic chemotherapy.
The effectiveness of one or the other agents as 1st and 2nd
line therapy for patients with metastatic breast cancer
(MBC) has often been reported in literature. But there is
dearth of reports of response to further lines of therapy.
However, we have seen in our experience[2] that response
to further lines of therapy is obtained even with develop-
ment of resistance to 1st and 2nd line therapy. This "resur-
rection of clinical efficacy" appears to be largely an
understatement in the present literature. We, therefore,
report relative efficacy of further endocrine agents in our
clinical series and aim to present an overview of available
clinico-pathological characteristics of tumours in patients
in this series who have had further clinical response fol-
lowing development of de novo and acquired resistance.
Patients and methods
Patients
Patients with MBC diagnosed and treated in our unit
between 1994 and 2004 had clinical and pathological
data collected prospectively and updated regularly on a
database. In this study, patients who fulfilled the follow-
ing criteria were investigated:
• Oestrogen receptor (ER) positive disease.
￿ With disease assessable by UICC criteria [3].
￿ First line therapeutic drug for metastatic disease was an
endocrine agent in postmenopausal women with addi-
tional goserelin in premenopausal women.
￿ In the presence of ER positive disease, endocrine therapy
was indicated at the outset due to the presence of non-vis-
ceral (predominantly bone only), non-rapidly progressive
disease and as later lines of therapy in patients who have
had clinical benefit with previous endocrine agents or
were not fit or unwilling to receive chemotherapy in the
presence of potentially life-threatening visceral metas-
tases. Where the patients were fit and willing for cytotoxic
chemotherapy in the presence of potentially life-threaten-
ing visceral metastases, further endocrine therapy was not
given.
￿ On treatment for at least 6 months unless they pro-
gressed prior (in which case they were deemed to have de
novo resistance).
￿ Patients were deemed to have progressed on endocrine
therapy if the assessable lesions progressed or the patients
developed new non-visceral or visceral lesions.
￿ When analysing the efficacy of endocrine agents in each
line of treatment, data of patients not treated with endo-
crine agents in that particular line were excluded and also
of those patients who were withdrawn earlier than 6
months owing to side-effects or those with incomplete
treatment data or follow-up data.
Use of bisphosphonates
￿ Bisphosphonates were used in women with bony metas-
tasis as per local guidelines. The agents used were Pamid-
ronate/Zoledronate and Clodronate.
Assessment of therapeutic response
￿ This was made as per UICC criteria. Assessable lesions
were deemed to have shown clinical benefit (CB) when
they either had objective response in the form of complete
response (CR) or partial response (PR); or had stable dis-
ease (SD) for ≥ 6 months [4,5].
￿ Duration of response (DOR) is the duration of treat-
ment of patients who have derived CB.
￿ Disease-free interval (DFI) is defined as the duration
from the date of treatment for the primary cancer to the
date of the first relapse regardless of its site.
Definitions of endocrine resistance
￿ de novo resistance – Patients whose disease progressed
within 6 months of treatment (i.e., never had CB from the
endocrine agent).
￿ Acquired resistance – Patients who progressed after at
least 6 months on treatment (i.e., having had CB from the
endocrine agent).
Methods
Two hundred and twenty three patients were eligible for
study. Available clinical and pathological data of these
patients was exported from the database onto SPSS™ soft-
ware (SPSS Inc. USA).
The degree of linear relationship between duration of
response and various variables was ascertained by Pear-
son's product-moment correlation coefficient (r). Bivari-
ate correlation was considered to be significant at 0.01
levels (2-tailed). Correlation was direct with positive coef-
ficient and inverse with negative coefficient.
Results
The comparison of clinico-pathological characteristics
between patients with de novo and acquired resistance toWorld Journal of Surgical Oncology 2006, 4:40 http://www.wjso.com/content/4/1/40
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1st line endocrine therapy is shown in Table 1. The differ-
ential use of endocrine agents in first 5 lines of therapy is
shown in Table 2A. The relative use of LHRH agonist
(Goserelin) when given to premenopausal women in
addition to other endocrine agents is shown in Table 2B.
Out of a total of 223 patients, the majority (71.3%) of
patients have had CB from 1st line endocrine therapy as
shown in Table 3A. The majority of patients who devel-
oped acquired resistance following CB to 1st line endo-
crine therapy went onto subsequent endocrine therapies
with further demonstrable CB as shown in Table 3B.
In those patients who had de novo resistance to 1st line
endocrine therapy but still went on to 2nd line endocrine
therapy, almost a third (29.4%) demonstrated CB with a
median DOR being 12.0 (7–29) months. The CB to sub-
sequent therapies following de novo resistance to 1st line
therapy is demonstrated in Table 4A. Further, among the
21 patients who had de novo resistance to 2nd line follow-
ing CB to 1st line endocrine therapy, 6 patients were put
on further lines of endocrine therapy with responses as
demonstrated in Table 4B.
Further analysis involved comparison between certain
available pathological characteristics of the de novo resist-
ant and acquired resistant groups (as in Table 1) in terms
of the DOR. The median DOR of patients on 1st line endo-
crine therapy correlated positively (r = 0.01) with the
length of DFI but correlated inversely (r = 0.01) with grade
3 tumours; pre-dominant presence of pleural metastasis,
lymphangitis and liver metastasis.
Discussion
As shown in previous randomised studies, majority of the
patients in our study had CB to 1st and 2nd lines of endo-
crine therapy. In addition, we demonstrate further
response to 3rd and 4th line endocrine therapy after CB to
previous 2 lines. The median DOR in all the 4 lines was
shown to be almost a year with the 1st line reaching 2
years.
Similarly, a proportion of patients who were treated with
2nd line endocrine therapy in spite of de novo resistance to
1st line endocrine therapy showed CB (almost a third)
with a median DOR of a year. They were treated with fur-
ther endocrine therapy either because of their individual
choice or because they had non-visceral (predominantly
bone only), non-rapidly progressive disease. A further
proportion of patients who were treated with 3rd line
endocrine therapy after de novo resistance yet again to 2nd
line had CB with a median DOR of more than a year.
However, there was no CB to 4th line therapy after lack of
CB to 1st three lines of endocrine therapy.
Table 1: Comparison of clinico-pathological characteristics between patients with de novo and acquired resistance to 1st line endocrine 
therapy
Acquired resistance de novo resistance
Total = 223 (100%) To 1st line To 1st line
CB (Clinical Benefit) 159 (71.3%) 64 (28.7)
Median duration of treatment in months 15.7+ 2.9
Median Age (Range) at metastasis in years 63.5 (30–89) 61.5 (32–87)
DFI (months) 58.0 (0–294) 36.5 (0–324)
Median Age (Range) at primary cancer in years 56.0 (26–86) 55.0 (28–87)
Maximum Size (Range) of tumour in mm. 24 (4–110) 27 (10–110)
Minimum Size (Range) of tumour in mm. 20 (2–70) 25 (10–75)
Histological lymph node stage(no. of positive nodes) 1 (0) 39.8 1 (0) 37.5
2 (1–3) 41.8 2 (1–3) 37.5
3 (≥4) 18.4 3 (≥4) 25.0
Grade (Elston/Ellis) 1 11.6 1 9.3
2 49.3 2 37.0
3 30.4 3 40.7
unknown 8.7 unknown 13.0
Vascular invasion 44.1% 50.0
Bony metastasis 61.5 60.3
Lung metastasis 21.4 23.9
Pleural metastasis 25.5 47.8
Lymphangitis 2.1 15.2
Liver metastasis 10.4 41.8
Other metastasis 35.2 28.8
+ = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; DFI = Disease free 
intervalWorld Journal of Surgical Oncology 2006, 4:40 http://www.wjso.com/content/4/1/40
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The rate of CB decreased with subsequent endocrine ther-
apy but responses were still seen to all 4 lines of therapy
irrespective of either acquired or de novo resistance to pre-
vious lines (except to 4th line with prior de novo resistance)
though the number of patients was small by that time.
Thus, "ultimate hormone resistance" does not appear to
occur in this series despite several (up to 4 lines) of endo-
crine therapy. Furthermore, when there is response, sus-
tained duration of CB is possible.
Although there was no statistical significance of the vari-
ous tumour or metastatic characteristics in predicting
response but they are suggestive of a trend especially in
relation to the prior DFI of the MBC patients. As seen in
the results, CB was obtained on 1st line of endocrine ther-
apy in those patients who had longer DFI and this was
true even with patients who were put on 2nd line endo-
crine therapy in spite of developing de novo resistance to
1st line. This is suggestive of an inherent, yet undefined
biological characteristic of the primary tumours which
lends it longer DFI and subsequent enhanced responsive-
ness to endocrine agents at a later metastatic stage.
Mechanism of development of resistance
Thus very similar to our results, it is known in literature
that in-spite of significant proportion of MBCs being ER
and/or progesterone receptor (PgR) positive, not all of
them respond to endocrine therapy suggesting underlying
intrinsic properties of the tumour and the underlying
mechanisms of intrinsic resistance i.e., de novo resistance
[6].
Various mechanisms of development of resistance have
been suggested by different scientific groups. Dowsett [7]
attributed the cause of de novo resistance to the presence of
only very low levels of ER and presumed growth depend-
ence on other pathways. However, with acquired resist-
ance, he noted that the intra-tumoral concentration of
tamoxifen was substantially reduced at relapse, despite no
change in plasma levels. Hardin et al [8] demonstrated
that dehydroepiandrosterone sulphate (DHEAS) expo-
sure, even in the presence of tamoxifen and fulvestrant,
induced changes in ER and PgR gene expression that may
be partially responsible for breast cancer progression.
Thus, the mechanisms of development of resistance are
from clear but there are ongoing efforts to develop mark-
ers or to identify tumour characteristics which may help
predicting type of response to endocrine
Predictive markers for type of response to endocrine 
therapy
In spite of their limitations, tumour grade and ER status
have been reported as independent predictors of response
to 1st line [9,10] and 2nd line [11] endocrine therapy.
Recently Bardou et al [12] have shown that PgR status is
an independent predictive factor for benefit from adju-
vant endocrine therapy and improves outcome prediction
of ER status.
Arpino et al [13] demonstrated in their study that patients
with HER-2 amplification and HER-1 expression had
lower ER levels and were modestly less responsive to
tamoxifen, suggesting that molecular events in addition to
those involving the ErbB receptors are important in deter-
mining the endocrine-resistant phenotype.
Table 2B: Relative use of LHRH agonist (Goserelin) in premenopausal patients in addition to other endocrine agents
Patients with 
Goserelin/Total 
patients treated 
each line (%)
1st line 31/223 
(13.9)
2nd line 5/115 (4.3) 3rd line 2/71 (2.8) 4th line 2/32 (6.2) 5th line 0/8 (0)
Tamoxifen 12 (5.4) None None 1 (3.1) None
Anastrozole 19 (8.5) 3 (2.6) None None None
Exemestane None 2 (1.7) 2 (2.8) 1 (3.1) None
Table 2A: Relative use of various endocrine agents
N (%) 1st line 223 (100) 2nd line 115 (100) 3rd line 71 (100) 4th line 32 (100) 5th line 8 (100)
Tamoxifen 85(38.1) 20(17.4) 5(7.0) 4(21.5) 2(25)
Anastrozole 110(49.3) 59(51.3) 12(17.0) 2(6.2) 2(25)
Exemestane 6(2.7) 24(20.9) 18(25.3) 18(56.3) 3(37.5)
Megestrol 5(2.7) 10(8.7) 35(49.3) 6(18.8) None
Fulvestrant 17(7.6) 2(1.7) 1(1.4) 2(6.2) None
Letrozole None None None None 1(12.5)World Journal of Surgical Oncology 2006, 4:40 http://www.wjso.com/content/4/1/40
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Significantly lower rate of response to 1st line endocrine
therapy was seen in patients with high vascular endothe-
lial growth factor (VEGF) levels (P = 0.025) [14] and high
levels of complex of urokinase-type plasminogen activa-
tor and its main inhibitor (P = 0.018) [15] when com-
pared with lower levels.
Jansen et al [16] recently demonstrated differential expres-
sion of 81 genes (P < or = 0.05) between tamoxifen-
responsive and resistant tumours in a study performed on
112 ER positive primary breast carcinomas from patients
with advanced disease and clearly defined types of
response (i.e., 52 patients with objective response versus
60 patients with progressive disease) from start of 1st line
treatment with tamoxifen. Gene expression profiling may
thus be used to predict differential response to endocrine
agents.
Accurate prediction of the type of response to endocrine
therapy would simplify the future planning and manage-
ment of MBC patients. Predictive markers can extend from
simple and available clinical indicators such as ER, PgR or
to some extent DFI as suggested in our dataset to more
complicated but specific gene expression profiling. How-
ever, till highly sensitive and yet specific predictive mark-
ers are available, optimal sequencing of endocrine agents'
based on available clinical data in literature has to be prac-
tised.
Optimal sequence of endocrine agents
With the availability of different endocrine agents, the
concept of sequencing becomes important so that we can
ensure optimal use of agents while maintaining hormone
sensitivity to subsequent agents which might act via differ-
ent mechanisms. Newer agents which challenge the "gold
standard" tamoxifen include 3rd  generation aromatase
inhibitors and oestrogen downregulators such as fulves-
trant. Further, endocrine response has been seen after ful-
vestrant has failed [17-19].
Traditionally, further endocrine therapy would only be
considered when CB has been seen with a prior agent.
This study demonstrates that further endocrine response
could still be seen in a significant proportion of patients
who have developed de novo resistance to 1st line endo-
crine therapy. This is an important observation to be
borne in mind when sequencing of endocrine agents is
considered.
Conclusion
The chance of further endocrine response continues to
decrease with each line of therapy, yet CB is still seen with
reasonable duration even with 3rd and 4th line agents; and
even after de novo resistance is apparent with prior endo-
crine agents.
The present study, therefore, exposes sufficient clinical
efficacy of further endocrine agents and "resurrection" of
their response even after the tumours have had de novo
resistance to previous lines of endocrine therapy. Based
on our finding, we would like to re-iterate that further
lines of endocrine agents should not be excluded in those
oestrogen receptor positive MBC patients who have not
had CB to previous endocrine agents. They may be partic-
ularly of benefit when these patients are not fit for aggres-
sive chemotherapy or not keen on chemotherapy pending
Table 3B: Clinical benefit achieved from subsequent lines of endocrine therapy in patients with clinical benefit to 1st line endocrine 
therapy
Lines of Endocrine therapy 2nd line 3rd line 4th line
N6 8 2 3 5
N of CB (%) 47 (69.1) 10 (43.5) 1(20.0)
Median DOR with CB (months) 12.0+(7–81) 11.0 (8–32) 15.0
N still receiving treatment 17 0 0
+ = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; 
DOR = Duration of Response
Table 3A: Clinical benefit achieved from 1st line endocrine therapy in all patients
Endocrine therapy 1st line
N2 2 3
N of CB (%) 159 (71.3%)
Median DOR with CB (months) 22+(7–117)
N still receiving treatment 50
+ = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; 
DOR = Duration of ResponseWorld Journal of Surgical Oncology 2006, 4:40 http://www.wjso.com/content/4/1/40
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availability of simple yet accurate endocrine response pre-
dictive markers or the availability of utopian resistance-
proof pharmaceutical product. This clinical study may be
instigative in initiation of larger prospective studies aimed
at defining intrinsic biological characteristics including
genetic profiling. This pre-treatment definition of tumour
may be predictive of the nature of response to planned
endocrine therapy.
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